Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results

被引：0
|
作者：
Hezode, Christophe
Ferenci, Peter
Dusheiko, Geoffrey M.
Tran, Albert
Grange, Jean-Didier
Mathurin, Philippe
Schmidt, Wolfgang E.
Diepolder, Helmut
Marcellin, Patrick
Wedemeyer, Heiner
Forestier, Nicole
Mangels, Wendy
Gharakhanian, Shahin
Kauffman, Robert S.
Alam, John
Pawlotsky, Jean-Michel
Zeuzem, Stefan
机构：
来源：
GASTROENTEROLOGY | 2008年 / 134卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A755 / A755
页数：1
相关论文
共 50 条
  • [21] Interim analysis of the safety and efficacy of peginterferon alfa-2a plus ribavirin in chronic hepatitis C patients unable to tolerate or nonresponsive to treatment with peginterferon alfa-2b plus ribavirin
    Rustgi, VK
    Esposito, S
    Freilich, B
    Lopez-Talavera, JC
    Lentz, E
    Shiffman, ML
    HEPATOLOGY, 2005, 42 (04) : 692A - 692A
  • [22] PHASE 2 STUDY OF TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR-ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE SUBJECTS WITH GENOTYPE 1 HEPATITIS C: WEEK 4 INTERIM RESULTS
    Forns, Xavier
    Marcellin, Patrick
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Vangeneugden, Tony J.
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2008, 48 (04) : 1136A - 1137A
  • [23] TELAPREVIR COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN HCV/HIV COINFECTED PATIENTS: 24-WEEK TREATMENT INTERIM ANALYSIS
    Sherman, Kenneth E.
    Rockstroh, Juergen K.
    Dieterich, Douglas T.
    Soriano, Vincent
    Girard, Pierre-Marie
    McCallister, Scott
    Adda, Nathalie
    Adiwijaya, Bambang S.
    Mahnke, Lisa
    Sulkowski, Mark S.
    HEPATOLOGY, 2011, 54 : 1431A - 1431A
  • [24] Pharmacoeconomic analysis of the treatment of chronic hepatitis C with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin in Spain
    Turnes, Juan
    Romero-Gomez, Manuel
    Planas, Ramon
    Sola, Ricard
    Garcia-Samaniego, Javier
    Diago, Moises
    Crespo, Javier
    Calleja, Jose Luis
    Rubio-Terres, Carlos
    Ventayol, Pere
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2013, 36 (09): : 555 - 564
  • [25] A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
    Flisiak, Robert
    Shiffman, Mitchell
    Arenas, Juan
    Cheinquer, Hugo
    Nikitin, Igor
    Dong, Yuping
    Rena, Khurram
    Srinivasan, Subasree
    PLOS ONE, 2016, 11 (10):
  • [26] Results of an interim analysis of a phase 2 study of telaprevir (VX-950) with peginterferon α-2a and ribavirin in previously untreated subjects with hepatitis C
    McHutchison, J. G.
    Everson, G. T.
    Gordo, S.
    Jacobson, R.
    Kauffman, R.
    McNair, L.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2007, 46 : S296 - S296
  • [27] Evaluation of viral variants during a Phase 2 study (PROVE2) of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive HCV genotype I-infected patients
    Kieffer, Tara
    Zhou, Yi
    Zhang, Eileen
    Marcial, Michelle
    Byrn, Randal
    Pfeiffer, Thomas
    Miller, Janice
    Tigges, Ann
    Bartels, Doug
    Kwong, Ann
    Ferenci, Peter
    Dusheiko, Geoffrey
    Zeuzem, Stefan
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2007, 46 (04) : 862A - 862A
  • [28] TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON-ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY
    Manns, M.
    Muir, A.
    Adda, N.
    Jacobson, I.
    Afdhal, N.
    Heathcote, J.
    Zeuzem, S.
    Reesink, H.
    Terrault, N.
    Bsharat, M.
    George, S.
    McHutchison, J.
    Di Bisceglie, A.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S379 - S379
  • [29] Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
    de Knegt, R. J.
    Bezemer, G.
    Van Gool, A. R.
    Drenth, J. P. H.
    Hansen, B. E.
    Fortuyn, H. A. Droogleever
    Weegink, C. J.
    Hengeveld, M. W.
    Janssen, H. L. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (11-12) : 1306 - 1317
  • [30] Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b
    Flisiak, Robert
    Kawazoe, Seiji
    Znoyko, Olga
    Assy, Nimer
    Gadano, Adrian
    Kao, Jia-Horng
    Lee, Kwan-Sik
    Zwirtes, Ricardo
    Portsmouth, Simon
    Dong, Yuping
    Xu, Dong
    Kumada, Hiromitsu
    Srinivasan, Subasree
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2016, 36 (11): : 635 - 643
12345